UnknownNot Applicable

Safety and Efficacy of Remote Ischemic Conditioning on Cerebral Amyloid Angiopathy. (RIC-CAA)

China30 participantsStarted 2022-01-20

Plain-language summary

Cerebral amyloid angiopathy (CAA) is a common form of cerebral small vessel disease, characterized by symptomatic intracerebral hemorrhage and cognitive impairment. However, no effective prevention and treatment strategies have been established. This study aims to evaluate the safety and efficacy of remote ischemic conditioning on patients with CAA.

Who can participate

Age range55 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age≥55 and ≤85.
✓. The diagnosis of probable CAA and probable CAA with supporting pathology by the Boston criteria.
✓. Signed and dated informed consented is obtained.

Exclusion criteria

✕. Familial hereditary CAA or other hereditary small-vessel disorders.
✕. Previous intracranial hemorrhage caused by other reasons, such as tumor, cerebral cavernous angioma, ruptured aneurysm, arteriovenous malformation, venous sinus thrombosis and so on.
✕. A history of stroke within 3 months.
✕. The degree of intracranial or extracranial large artery stenosis \>50%.
✕. Clinical diagnosis of probable AD by National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
✕. Significant cognitive impairment (defined as Mini-mental State Examination (MMSE) score of ≥20 (primary school) or ≥24 (junior school or above) or other diseases resulting from severe cognitive impairment.
✕. Inability to walk 6m unaided or other conditions that affected gait performance, such as Parkinson.
✕. Illiteracy and patients with severe visual or hearing impairment.

What they're measuring

Changes of volume of WMHs.

Timeframe: From baseline to 6 months and 1 year treatment.

Trial details

NCT IDNCT05207475

SponsorCapital Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-01-20

Contact for this trial

Xunming Ji, MD PhD

010-83199430 jixm@ccmu.edu.cn

View on ClinicalTrials.gov More Cerebral Amyloid Angiopathy trials